Brick & Kyle Associates Raises Stake in Pfizer Inc. (NYSE:PFE)
Brick & Kyle Associates lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 9.1% in the first quarter, HoldingsChannel.com reports. The firm owned 9,747 shares of the biopharmaceutical company’s stock after purchasing an additional 814 shares during the period. Brick & Kyle Associates’ holdings in Pfizer were worth $414,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Pfizer by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after purchasing an additional 6,620,749 shares during the period. Vanguard Group Inc boosted its holdings in Pfizer by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after acquiring an additional 6,620,749 shares during the period. Bank of New York Mellon Corp boosted its holdings in Pfizer by 3.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 70,231,649 shares of the biopharmaceutical company’s stock worth $3,095,110,000 after acquiring an additional 2,497,736 shares during the period. Fisher Asset Management LLC boosted its holdings in Pfizer by 3.3% in the 4th quarter. Fisher Asset Management LLC now owns 41,830,709 shares of the biopharmaceutical company’s stock worth $1,825,910,000 after acquiring an additional 1,352,978 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Pfizer by 1.1% in the 3rd quarter. Legal & General Group Plc now owns 27,673,602 shares of the biopharmaceutical company’s stock worth $1,219,562,000 after acquiring an additional 309,817 shares during the period. Institutional investors and hedge funds own 71.88% of the company’s stock.
Shares of PFE traded up $0.26 during trading on Friday, reaching $42.76. The company’s stock had a trading volume of 12,521,684 shares, compared to its average volume of 20,710,772. Pfizer Inc. has a twelve month low of $35.73 and a twelve month high of $46.47. The firm has a market cap of $237.74 billion, a price-to-earnings ratio of 14.25, a PEG ratio of 2.47 and a beta of 0.65. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 7th. Shareholders of record on Friday, May 10th were given a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s payout ratio is 48.00%.
A number of research firms have weighed in on PFE. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 3rd. Bank of America upped their price target on Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Citigroup restated a “neutral” rating and issued a $41.00 price target on shares of Pfizer in a report on Wednesday, February 20th. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a report on Tuesday, February 19th. Finally, Goldman Sachs Group began coverage on Pfizer in a report on Tuesday, May 28th. They issued a “conviction-buy” rating for the company. Thirteen equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $46.00.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the transaction, the insider now directly owns 124,994 shares of the company’s stock, valued at approximately $5,353,493.02. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction on Monday, May 13th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Green Investing
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.